On May 18, 2020 VBL Therapeutics (Nasdaq: VBLT) reported that new data suggesting the potential of its proprietary bi-specific antibodies for immune-mediated targeting of solid tumors will be presented at the Annual American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, to be held June 22–24, 2020 (Press release, VBL Therapeutics, MAY 18, 2020, View Source [SID1234558223]). VBL’s data show that MOSPD2 bi-specific antibodies induce T-cell activation and significantly extend the survival of mice carrying established metastatic cervical cancer, with no evidence of toxicity.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
VBL’s research has identified MOSPD2 as a protein involved in cell motility, whose expression is highly elevated in various solid tumors. The proprietary bi-specific antibodies developed by VBL have two separate arms – one arm binds to MOSPD2 on tumor cells and the second recruits host T-cells that attack the tumor. The new data to be presented at AACR (Free AACR Whitepaper) highlight the potential of bi-specific mediated immuno-oncology investigational therapy for the treatment of various MOSPD2-expressing solid tumors.
Details for the AACR (Free AACR Whitepaper) 2020 Virtual Meeting II presentations are as follows :
Permanent Abstract Number: LB-086
Title: CD3 MOSPD2 bi-specific antibody significantly prolongs survival in a model of metastatic human cervical cancer without any evidence of toxicity
Authors: Yacov et al.
Session Type: Poster Session
Session Category: Immunology
Session Title: Late-Breaking Research: Immunology 1
Permanent Abstract Number: 5592
Title: MOSPD2 a novel target for bi-specific antibody mediated solid tumor cells immune death
Authors: Salem et al.
Session Type: Poster Session
Session Category: Immunology
Session Title: Inflammation, Immunity, and Cancer / Modifiers of the Tumor Microenvironment 2
VBL’s presentations will be available on the AACR (Free AACR Whitepaper) e-poster website on June 22, 2020.
About VBL’s VB-600 Platform
VBL is conducting two parallel drug development programs that are exploring the potential of MOSPD2 (motile sperm domain-containing protein 2), a protein that VBL has identified as a key regulator of cell motility, as a therapeutic target for inflammatory diseases and cancer. Our VB-600 platform comprises classical anti-MOSPD2 investigational monoclonal antibodies for inflammatory indications, as well as bi-specific antibody candidates for oncology.